Monsanto Ordered to Pay Over $80 Million in Roundup Cancer Case
The second phase of the bifurcated trial determining whether Monsanto should be held liable for the non-Hodgkins lymphoma suffered by a man after using the Monsanto product Roundup for decades has concluded. The culmination of the trial resulted in a jury award of over $5.6 million in compensatory damages and $200,000 for medical expenses to the plaintiff, and $75 million in punitive damages. The damages awarded are not only meant to compensate the plaintiff for the harm he suffered, but also to punish Monsanto for inappropriate conduct related to the product. While Bayer, the company that purchased Monsanto, issued a statement that it did not believe the subject case would impact future cases, the opposite is most likely true. Although each case must be assessed on its unique facts, it is probable that the subject case will have far-reaching effects on cases throughout the country in which it is alleged that Roundup caused a plaintiff’s harm, including Illinois toxic tort cases.
Evidence Presented in the Second Phase